Padavano Julianna, Henkhaus Rebecca S, Chen Hwudaurw, Skovan Bethany A, Cui Haiyan, Ignatenko Natalia A
Department of Biochemistry and Molecular Biophysics, Undergraduate Biology Research Program, University of Arizona, Tucson, Arizona, USA.
Cancer Biology Interdisciplinary Program, University of Arizona Cancer Center, Tucson, AZ, USA.
Cancer Growth Metastasis. 2015 Oct 19;8(Suppl 1):95-113. doi: 10.4137/CGM.S29407. eCollection 2015.
Pancreatic ductal adenocarcinoma is one of the most aggressive malignancies, characterized by the local invasion into surrounding tissues and early metastasis to distant organs. Oncogenic mutations of the K-RAS gene occur in more than 90% of human pancreatic cancers. The goal of this study was to investigate the functional significance and downstream effectors of mutant K-RAS oncogene in the pancreatic cancer invasion and metastasis. We applied the homologous recombination technique to stably disrupt K-RAS oncogene in the human pancreatic cell line MiaPaCa-2, which carries the mutant K-RAS (G12C) oncogene in both alleles. Using in vitro assays, we found that clones with disrupted mutant K-RAS gene exhibited low RAS activity, reduced growth rates, increased sensitivity to the apoptosis inducing agents, and suppressed motility and invasiveness. In vivo assays showed that clones with decreased RAS activity had reduced tumor formation ability in mouse xenograft model and increased survival rates in the mouse orthotopic pancreatic cancer model. We further examined molecular pathways downstream of mutant K-RAS and identified RhoA GTP activating protein 5, caveolin-1, and RAS-like small GTPase A (RalA) as key effector molecules, which control mutant K-RAS-dependent migration and invasion in MiaPaCa-2 cells. Our study provides rational for targeting RhoA and RalA GTPase signaling pathways for inhibition of pancreatic cancer metastasis.
胰腺导管腺癌是最具侵袭性的恶性肿瘤之一,其特征是局部侵犯周围组织并早期转移至远处器官。超过90%的人类胰腺癌发生K-RAS基因的致癌突变。本研究的目的是探讨突变型K-RAS癌基因在胰腺癌侵袭和转移中的功能意义及下游效应分子。我们应用同源重组技术在人胰腺细胞系MiaPaCa-2中稳定破坏K-RAS癌基因,该细胞系的两个等位基因均携带突变型K-RAS(G12C)癌基因。通过体外实验,我们发现突变型K-RAS基因被破坏的克隆表现出低RAS活性、生长速率降低、对凋亡诱导剂的敏感性增加以及运动性和侵袭性受到抑制。体内实验表明,RAS活性降低的克隆在小鼠异种移植模型中的肿瘤形成能力降低,在小鼠原位胰腺癌模型中的存活率增加。我们进一步研究了突变型K-RAS下游的分子途径,确定RhoA GTP激活蛋白5、小窝蛋白-1和RAS样小GTP酶A(RalA)为关键效应分子,它们控制MiaPaCa-2细胞中依赖突变型K-RAS的迁移和侵袭。我们的研究为靶向RhoA和RalA GTP酶信号通路抑制胰腺癌转移提供了理论依据。